Back to results

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Primary Purpose

Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, Metastatic NSCLC

Status

Completed

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

Cabazitaxel-XRP6258 (3-week cycle)

Cabazitaxel-XRP6258 (5-week cycle)

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer (NSCLC) focused on measuring Non-small cell lung cancer, Cabazitaxel-XRP6258, P-glycoprotein, taxane, Advanced NSCLC

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Histologic or cytologic diagnosis of NSCLC (squamous or non-squamous or NSCLC-not specified)
Subjects who have failed first line chemotherapy (platinum doublets or non- platinum doublets [previous taxane exposure is allowed]) for Stage IV NSCLC.
Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Age > 18 years old
Adequate bone marrow, liver and renal function, defined as:
- Absolute neutrophil count (ANC) greater than or equal to 1500/ul
- Hemoglobin greater than or equal to 10 g/dl
- Platelet count greater than or equal to 100,000/ul
- Total bilirubin less than or equal to 1.5 x upper limit of normal (except in subjects with documented Gilbert's syndrome)
- AST/ALT less than or equal to 1.5 x upper limit of normal
- Serum creatinine less than or equal to 1.8 mg/dl
Fully recovered from any previous surgery (at least 4 weeks since major surgery)
Fully recovered from previous radiation therapy (at least 2 weeks)
All subjects must agree to practice approved methods of birth control (if applicable). A negative pregnancy test must be documented during the screening period for women of childbearing potential.
Written informed consent and authorization to use and disclose health information (HIPAA) must be signed by the subject.
Subjects with symptomatic brain metastases should be adequately treated and controlled prior to the initiation of the study. Subjects with asymptomatic brain metastases will be allowed in the study without any prior therapy for brain metastases.

Exclusion Criteria:

Concurrent cancer chemotherapy, biologic therapy or radiotherapy
Administration of any investigational agent within 28 days prior to administration of current therapy
Untreated symptomatic brain metastases
Greater than or equal to Grade 2 neuropathy
Concurrent serious infection
Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor, which is likely to compromise subject safety and affect the outcome of the study.
Treatment for a cancer other the NSCLC within 5 years prior to enrollment, with the exception of basal cell carcinoma or carcinoma in situ of the cervix
Any evidence of history of hypersensitivity for the taxane class of chemotherapy drugs
History of positive serology for HIV
Psychiatric disorder that prevents subjects from providing informed consent or following protocol instructions
Pregnant or lactating women

Sites / Locations

University of Alabama at Birmingham
Georgia Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

Schedule A

Schedule B

Arm Description

Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258. Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases.

Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A. Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases.

Outcomes

Primary Outcome Measures

Objective Response Rate

The objective response is defined as the percentage of patients that achieve a complete and/or partial response according to The Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1).

Secondary Outcome Measures

Progression Free Survival

Progression Free Survival is defined from the initiation of treatment until radiological-clinical evidence of progression according to the RECIST (v 1.1).

Number of Patients With Any Graded Adverse Event

Safety will be assessed using the National Cancer Institute Common Toxicity Criteria (Version 4.0) and all adverse events will be recorded prior to each treatment regimen.

Overall Survival

Assessment will be made in subjects with Stage IV NSCLC who receive Cabazitaxel-SRP6258 after progressing with first line platinum-based chemotherapy.

Full Information

NCT ID

NCT01438307

First Posted

September 15, 2011

Last Updated

April 24, 2017

Sponsor

University of Alabama at Birmingham

Collaborators

Sanofi

1. Study Identification

Unique Protocol Identification Number

NCT01438307

Brief Title

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Official Title

Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Study Type

Interventional

2. Study Status

Record Verification Date

April 2017

Overall Recruitment Status

Completed

Study Start Date

September 2011 (undefined)

Primary Completion Date

September 2014 (Actual)

Study Completion Date

September 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

University of Alabama at Birmingham

Collaborators

Sanofi

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Lung cancer is the leading cause of cancer death worldwide and in the United States. The majority of lung cancers are non-small cell lung cancer (NSCLC). The majority of NSCLC cases are advanced at the time of diagnosis. Chemotherapy has improved overall survival but remains limited at < 12 months median overall survival. New approaches are needed for second line chemotherapy treatment. Cabazitaxel-XRP6258 has shown increased overall survival in metastatic prostate cancer and it is hopeful it can do the same in advanced NSCLC.

Detailed Description

A substantial number of patients with lung cancer progress after first line treatment and require second line chemotherapy. Lung cancer appears to account for 40-50% of all known brain metastasis. The incidence of brain metastases among lung cancer patients ranges from 16-20%. Chemotherapy has had limited utility due to problems crossing the blood brain barrier. Currently there are three drugs approved by the FDA for second line treatment of NSCLC but each has distinct toxicities. Cabazitaxel-XRP6258 is a potent novel taxane with enhanced activity against an increased number of cell lines including lung, prostate, colon, pancreas, head and neck, kidney, gastric, glioblastoma, and melanoma. It also has the ability to cross the blood brain barrier. Cabazitaxel-XRP6258 was found to have an improved antiproliferative activity than other chemotherapy agents against insensitive cell lines. The Phase I studies of Cabazitaxel-SRP6258 have determined dosage and schedule recommendations in advanced NSCLC patients to be utilized for a Phase II multicenter study. Subjects will be placed on one of two schedules (A or B) each with a specified dosage and administration schedule. All subjects will be followed for survival/progression after every 2 cycles of therapy with imaging studies. A two stage design will be used for each of the two schedules. Fourteen subjects will be accrued for each schedule in the first stage with possible accrual of an additional 34 subjects per schedule depending upon the first stage results.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, Metastatic NSCLC

Keywords

Non-small cell lung cancer, Cabazitaxel-XRP6258, P-glycoprotein, taxane, Advanced NSCLC

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

28 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Schedule A

Arm Type

Experimental

Arm Description

Arm Title

Schedule B

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Cabazitaxel-XRP6258 (3-week cycle)

Other Intervention Name(s)

Jevtana

Intervention Description

Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.

Intervention Type

Drug

Intervention Name(s)

Cabazitaxel-XRP6258 (5-week cycle)

Other Intervention Name(s)

Jevtana

Intervention Description

Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.

Primary Outcome Measure Information:

Title

Objective Response Rate

Description

The objective response is defined as the percentage of patients that achieve a complete and/or partial response according to The Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1).

Time Frame

Baseline up to 28 months

Secondary Outcome Measure Information:

Title

Progression Free Survival

Description

Progression Free Survival is defined from the initiation of treatment until radiological-clinical evidence of progression according to the RECIST (v 1.1).

Time Frame

Baseline up to 28 months

Title

Number of Patients With Any Graded Adverse Event

Description

Safety will be assessed using the National Cancer Institute Common Toxicity Criteria (Version 4.0) and all adverse events will be recorded prior to each treatment regimen.

Time Frame

Baseline up to 28 months

Title

Overall Survival

Description

Assessment will be made in subjects with Stage IV NSCLC who receive Cabazitaxel-SRP6258 after progressing with first line platinum-based chemotherapy.

Time Frame

28 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

19 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Histologic or cytologic diagnosis of NSCLC (squamous or non-squamous or NSCLC-not specified) Subjects who have failed first line chemotherapy (platinum doublets or non- platinum doublets [previous taxane exposure is allowed]) for Stage IV NSCLC. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Age > 18 years old Adequate bone marrow, liver and renal function, defined as: Absolute neutrophil count (ANC) greater than or equal to 1500/ul Hemoglobin greater than or equal to 10 g/dl Platelet count greater than or equal to 100,000/ul Total bilirubin less than or equal to 1.5 x upper limit of normal (except in subjects with documented Gilbert's syndrome) AST/ALT less than or equal to 1.5 x upper limit of normal Serum creatinine less than or equal to 1.8 mg/dl Fully recovered from any previous surgery (at least 4 weeks since major surgery) Fully recovered from previous radiation therapy (at least 2 weeks) All subjects must agree to practice approved methods of birth control (if applicable). A negative pregnancy test must be documented during the screening period for women of childbearing potential. Written informed consent and authorization to use and disclose health information (HIPAA) must be signed by the subject. Subjects with symptomatic brain metastases should be adequately treated and controlled prior to the initiation of the study. Subjects with asymptomatic brain metastases will be allowed in the study without any prior therapy for brain metastases. Exclusion Criteria: Concurrent cancer chemotherapy, biologic therapy or radiotherapy Administration of any investigational agent within 28 days prior to administration of current therapy Untreated symptomatic brain metastases Greater than or equal to Grade 2 neuropathy Concurrent serious infection Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor, which is likely to compromise subject safety and affect the outcome of the study. Treatment for a cancer other the NSCLC within 5 years prior to enrollment, with the exception of basal cell carcinoma or carcinoma in situ of the cervix Any evidence of history of hypersensitivity for the taxane class of chemotherapy drugs History of positive serology for HIV Psychiatric disorder that prevents subjects from providing informed consent or following protocol instructions Pregnant or lactating women

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Francisco Robert, MD

Organizational Affiliation

University of Alabama at Birmingham

Official's Role

Principal Investigator

Facility Information:

Facility Name

University of Alabama at Birmingham

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35294

Country

United States

Facility Name

Georgia Cancer Center

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30060

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

We'll reach out to this number within 24 hrs